Related Experiment Video
Updated: Nov 16, 2025

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
Published on: October 3, 2019
Characterization of the Platelet Phenotype Caused by a Germline RUNX1 Variant in a CRISPR/Cas9-Generated Murine Model
Ana Marín-Quílez1, Ignacio García-Tuñón1, Cristina Fernández-Infante1
1Cancer Research Center - CSIC, Instituto de Investigación Biomédica de Salamanca, University of Salamanca, Salamanca, Spain.
Insights
RUNX1-related disorder (RUNX1-RD) is caused by variants in the RUNX1 gene. A new mouse model shows the RUNX1 p.Leu56Ser variant impairs platelet function, mimicking human disease phenotypes.
Area of Science:
- Genetics
- Hematology
- Molecular Biology
Background:
- RUNX1-related disorder (RUNX1-RD) results from germline variants in the RUNX1 gene, presenting a diagnostic challenge due to its heterogeneous nature and lack of a specific phenotype.
- International guidelines exist for variant classification, but determining pathogenicity and understanding molecular pathogenesis for RUNX1-RD requires further investigation.
Purpose of the Study:
- To develop and characterize a knock-in murine model for the RUNX1 p.Leu43Ser variant (human p.Leu56Ser) to investigate its pathogenic effects on platelet function.
- To elucidate the molecular mechanisms underlying platelet dysfunction in RUNX1-RD.
Main Methods:
- CRISPR/Cas9 gene editing was used to create a knock-in mouse model with the RUNX1 p.Leu43Ser variant.
- Generated three genotypes: RUNX1 wild-type/wild-type (WT/WT), RUNX1 WT/L43S, and RUNX1 L43S/L43S.
- Assessed platelet phenotype using flow cytometry, confocal microscopy, tail-bleeding time, agonist-induced spreading, granule secretion, integrin activation, and PKC phosphorylation.
Main Results:
- Mice with the RUNX1 L43S variant (homozygous and heterozygous) exhibited prolonged tail-bleeding times, indicating impaired hemostasis.
- Homozygous mice showed mild thrombocytopenia. Both variant genotypes displayed impaired agonist-induced platelet spreading and alpha-granule release.
- Deficits in integrin αIIbβ3 activation, fibrinogen binding, and aggregation were observed, alongside reduced PKC phosphorylation, suggesting impaired PKC signaling.
Conclusions:
- The RUNX1 p.Leu56Ser variant has deleterious effects in mice, impairing key platelet functions such as integrin activation, aggregation, and granule secretion.
- This murine model successfully mimics clinical phenotypes associated with RUNX1 variants, providing a valuable tool for studying RUNX1-RD pathogenesis.
- The findings highlight the role of the PKC signaling pathway in RUNX1-mediated platelet dysfunction.
Abstract:
RUNX1-related disorder (RUNX1-RD) is caused by germline variants affecting the RUNX1 gene. This rare, heterogeneous disorder has no specific clinical or laboratory phenotype, making genetic diagnosis necessary. Although international recommendations have been established to classify the pathogenicity of variants, identifying the causative alteration remains a challenge in RUNX1-RD. Murine models may be useful not only for definitively settling the controversy about the pathogenicity of certain RUNX1 variants, but also for elucidating the mechanisms of molecular pathogenesis. Therefore, we developed a knock-in murine model, using the CRISPR/Cas9 system, carrying the RUNX1 p.Leu43Ser variant (mimicking human p.Leu56Ser) to study its pathogenic potential and mechanisms of platelet dysfunction. A total number of 75 mice were generated; 25 per genotype (RUNX1WT/WT, RUNX1WT/L43S, and RUNX1L43S/L43S). Platelet phenotype was assessed by flow cytometry and confocal microscopy. On average, RUNX1L43S/L43S and RUNX1WT/L43S mice had a significantly longer tail-bleeding time than RUNX1WT/WT mice, indicating the variant's involvement in hemostasis. However, only homozygous mice displayed mild thrombocytopenia. RUNX1L43S/L43S and RUNX1WT/L43S displayed impaired agonist-induced spreading and α-granule release, with no differences in δ-granule secretion. Levels of integrin αIIbβ3 activation, fibrinogen binding, and aggregation were significantly lower in platelets from RUNX1L43S/L43S and RUNX1WT/L43S using phorbol 12-myristate 13-acetate (PMA), adenosine diphosphate (ADP), and high thrombin doses. Lower levels of PKC phosphorylation in RUNX1L43S/L43S and RUNX1WT/L43S suggested that the PKC-signaling pathway was impaired. Overall, we demonstrated the deleterious effect of the RUNX1 p.Leu56Ser variant in mice via the impairment of integrin αIIbβ3 activation, aggregation, α-granule secretion, and platelet spreading, mimicking the phenotype associated with RUNX1 variants in the clinical setting.
More Related Videos
08:27Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
Published on: April 10, 2018
09:16Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019